Medical World News® Inside the Practice: CancerNetwork® and Albert H. Kim, MD, PhD, on Treating Brain Tumor Malignancies at the Siteman Cancer Center

Video

CancerNetwork® spoke with Albert H. Kim, MD, PhD, about a new Brain Tumor Center at Siteman, for which he is the inaugural director.

For the latest installment of the Inside the Practice segment of the Medical World News® broadcast, CancerNetwork® spoke with Albert H. Kim, MD, PhD, of the Washington University School of Medicine and Barnes-Jewish Hospital, about the newly established Brain Tumor Center at the Siteman Cancer Center. The center will bring together multidisciplinary specialists in neurosurgery, medicine, radiation oncology, pathology, immunology, otolaryngology, and endocrinology to conduct cutting-edge research

In the interview, Kim talked about a new neuroscience building on the medical campus that will eventually house the center as well as 100 or so laboratories for clinical research.

The center also offers some leading-edge treatment techniques, like proton beam therapy for malignancies in adult and pediatric patients, that may offer options not yet available at other institutions.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.

Recent Videos
Raymond B. Mailhot, MD, MPH, discussed how radiation therapy can impact education and survivorship for pediatric survivors of brain tumors.
Significant results from a retrospective analysis of brain tumor survivor academic performance after radiotherapy emerged despite small sampling size.
Raymond B. Mailhot, MD, MPH, discussed methods for comparing academic performances of patients following radiation therapy with healthy control groups.
The act of asking for help is critical to finding mentors who can help one advance in the brain cancer field, according to Yoshie Umemura, MD.
Through multidisciplinary collaboration, Yoshie Umemura, MD, and colleagues were able to organize the Gliofocus trial in brain cancer relatively fast.
Yoshie Umemura, MD, discusses how multiple departments can positively impact a patient with brain cancer during their visit to a medical center.
Antibody-drug conjugates and small molecule inhibitors may show utility in the neuro-oncology field, according to Nader Sanai, MD.
The phase 3 Gliofocus trial aims to meaningfully improve survival and quality of life with niraparib among patients with newly diagnosed glioblastoma.
Findings from a proof-of-concept study show a potential survival benefit with niraparib/radiotherapy in patients with newly diagnosed glioblastoma.
ZAP-X may provide submillimeter accuracy when administering radiation to patients with brain tumors.